ANI Pharma (ANIP) Misses Q4 EPS by 14c, Revenue Beats

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $0.80, $0.14 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $57.3 million versus the consensus estimate of $54.27 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• Ennis (EBF) Reports In-Line Q1 EPS